ANTI NMO NEUROMYELITIS OPTICA PANEL CSF Test
Price: 1200.0 AED
Sample Condition: 1 mL (0.5 mL min.) CSF in a sterile screw capped container. Ship refrigerated or frozen.
Report Delivery: Sample Tue / Fri by 9 am; Report Same day
Method: Cell based assay, IFA
Test Type: Disorders of Nervous System
Doctor: Neurologist
Test Department: IMMUNOPATHOLOGY
Pre Test Information: No special preparation required
Test Details
The anti-NMO (neuromyelitis optica) panel CSF test is a diagnostic test used to identify antibodies associated with neuromyelitis optica (NMO), also known as Devic’s disease. NMO is an autoimmune disorder that primarily affects the optic nerves and spinal cord.
The test involves analyzing the cerebrospinal fluid (CSF), which is the clear fluid that surrounds the brain and spinal cord, for the presence of specific antibodies called aquaporin-4 (AQP4) antibodies. These antibodies are found in about 70-80% of individuals with NMO and are believed to play a role in the development of the disease.
The anti-NMO panel CSF test is typically performed in individuals suspected of having NMO or those with unexplained optic neuritis or myelitis. It helps differentiate NMO from other similar conditions like multiple sclerosis (MS) and provides valuable information for accurate diagnosis and appropriate treatment.
During the test, a sample of CSF is collected through a lumbar puncture or spinal tap procedure. The CSF sample is then analyzed in a laboratory using various techniques, such as enzyme-linked immunosorbent assay (ELISA) or cell-based assays, to detect the presence of AQP4 antibodies.
A positive result indicating the presence of AQP4 antibodies suggests a higher likelihood of NMO. However, it is important to note that not all individuals with NMO will test positive for AQP4 antibodies, and some individuals without NMO may have these antibodies as well. Therefore, the test results should be interpreted in conjunction with the individual’s clinical symptoms and other diagnostic findings.
The anti-NMO panel CSF test plays a crucial role in the diagnosis and management of NMO, as it helps guide treatment decisions and monitor disease activity. Early detection and appropriate treatment can help prevent severe neurological damage and improve outcomes for individuals with NMO.
| Test Name | ANTI NMO NEUROMYELITIS OPTICA PANEL CSF Test |
|---|---|
| Components | *Anti Aquaporin 4*Anti MOG |
| Price | 1200.0 AED |
| Sample Condition | 1 mL (0.5 mL min.) CSF in a sterile screw capped container. Ship refrigerated or frozen. |
| Report Delivery | SampleTue / Fri by 9 am; Report Same day |
| Method | Cell based assay, IFA |
| Test type | Disorders of Nervous System |
| Doctor | Neurologist |
| Test Department: | IMMUNOPATHOLOGY |
| Pre Test Information | No special preparation required |
| Test Details |
The anti-NMO (neuromyelitis optica) panel CSF test is a diagnostic test used to identify antibodies associated with neuromyelitis optica (NMO), also known as Devic’s disease. NMO is an autoimmune disorder that primarily affects the optic nerves and spinal cord. The test involves analyzing the cerebrospinal fluid (CSF), which is the clear fluid that surrounds the brain and spinal cord, for the presence of specific antibodies called aquaporin-4 (AQP4) antibodies. These antibodies are found in about 70-80% of individuals with NMO and are believed to play a role in the development of the disease. The anti-NMO panel CSF test is typically performed in individuals suspected of having NMO or those with unexplained optic neuritis or myelitis. It helps differentiate NMO from other similar conditions like multiple sclerosis (MS) and provides valuable information for accurate diagnosis and appropriate treatment. During the test, a sample of CSF is collected through a lumbar puncture or spinal tap procedure. The CSF sample is then analyzed in a laboratory using various techniques, such as enzyme-linked immunosorbent assay (ELISA) or cell-based assays, to detect the presence of AQP4 antibodies. A positive result indicating the presence of AQP4 antibodies suggests a higher likelihood of NMO. However, it is important to note that not all individuals with NMO will test positive for AQP4 antibodies, and some individuals without NMO may have these antibodies as well. Therefore, the test results should be interpreted in conjunction with the individual’s clinical symptoms and other diagnostic findings. The anti-NMO panel CSF test plays a crucial role in the diagnosis and management of NMO, as it helps guide treatment decisions and monitor disease activity. Early detection and appropriate treatment can help prevent severe neurological damage and improve outcomes for individuals with NMO. |
